CINCINNATI--(BUSINESS WIRE)--Feb. 16, 2012--
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian
Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the latest addition
to its SensiFAST family real-time PCR products.
SensiFAST HRM Kit facilitates High Resolution Melt (HRM) curve analysis,
enabling amplification and discrimination of even the most challenging
sequence differences (such as class 4 SNPs) without sequence preference.
SensiFAST HRM is designed to deliver fast, accurate detection of gene
mutations and SNPs and provides reliable and highly reproducible data on
all commonly used real-time PCR instruments, especially the new
generation of fast-cyclers. Since SensiFAST HRM does not require
expensive labeled oligonucleotide probes, it is a cost-effective
alternative to traditional probe based genotyping methods.
Marco Calzavara, President of Bioline commented, "I am delighted to
announce the release of SensiFAST HRM as a new member of our real-time
PCR-based SensiFAST family. This new kit will enable researchers to
cost-effectively scan DNA from a variety of biological sample types to
detect the smallest genetic variations among samples.”
Richard L. Eberly, Chief Commercial Officer of Meridian Bioscience,
Inc., stated, “The release of SensiFAST HRM Kit is part of a new
generation of products to advance the rapidly expanding portfolio of
highly specialized molecular biology reagents from Bioline. We remain
committed to our life science customers to bring innovation and quality
products to the research lab, clinical diagnostic laboratories, and
ABOUT MERIDIAN BIOSCIENCE, INC.
Meridian is a fully integrated life science company that manufactures,
markets and distributes a broad range of innovative diagnostic test
kits, purified reagents and related products and offers
biopharmaceutical enabling technologies. Utilizing a variety of methods,
these products and diagnostic tests provide accuracy, simplicity and
speed in the early diagnosis and treatment of common medical conditions,
such as gastrointestinal, viral and respiratory infections. Meridian’s
diagnostic products are used outside of the human body and require
little or no special equipment. The Company's products are designed to
enhance patient well-being while reducing the total outcome costs of
healthcare. Meridian has strong market positions in the areas of
gastrointestinal and upper respiratory infections, serology,
parasitology and fungal disease diagnosis. In addition, Meridian is a
supplier of rare reagents, specialty biologicals and related
technologies used by biopharmaceutical companies engaged in research for
new drugs and vaccines. The Company markets its products and
technologies to hospitals, reference laboratories, research centers,
veterinary testing centers, diagnostics manufacturers and biotech
companies in more than 60 countries around the world. The Company’s
shares are traded through NASDAQ’s Global Select Market, symbol VIVO.
Meridian's website address is www.meridianbioscience.com.
For more information about Bioline, please visit www.bioline.com
more information about Meridian Life Science, Inc., please visit www.meridianlifescience.com
more information about Meridian Bioscience, Inc., please visit www.meridianbioscience.com
Source: Meridian Bioscience, Inc.
Meridian Bioscience, Inc.
Richard L. Eberly, Chief Commercial